BioCentury
ARTICLE | Company News

Opthotech gains gene therapy for ophran vision-loss disease

June 8, 2018 3:27 PM UTC

Ophthotech Corp. (NASDAQ:OPHT) acquired exclusive, worldwide rights to develop and commercialize a preclinical ophthalmic gene therapy from the University of Florida Research Foundation and the University of Pennsylvania.

The deal gives the biotech an adeno-associated virus (AAV) gene therapy to treat rhodopsin (RHO; OPN2)-mediated autosomal dominant retinitis pigmentosa. The AAV is designed to knock down mutant RHO expression and deliver a functional replacement gene...